Induced Sputum Substance P in Children with Difficult-to-Treat Bronchial Asthma and Gastroesophageal Reflux: Effect of Esomeprazole Therapy

Table 4

ACT, FEV₁, PEF variability, and induced sputum SP in children with difficult-to-treat asthma with GERD treated with esomeprazole and children with difficult-to-treat asthma without GERD treated with placebo before and after treatment.

	Before treatment	After treatment	t	P
Children with difficult-to-treat asthma and GERD (n 29)
C-ACT	12.7±3.99	15.03±4.4	11.6	<0.001*
FEV1 (% of predicted)	57.1±7.9	57.6±7.6	1.2	>0.05
PEF variability (%)	40.7±5.5	40.3±5.2	1.6	>0.05
SP (pg/mL)	1502±83.6	1198±223.5	9.4	<0.001*
Children with difficult-to-treat asthma without GERD (n 30)
C-ACT	12.9±3.3	12.7±2.9	1.97	>0.05
FEV1 (% of predicted)	60.2±4.6	60.4±4.5	0.59	>0.05
PEF variability (%)	39.3±3.6	38.9±3.2	1.6	>0.05
SP (pg/mL)	1.68.6±65.3	1067.6±67.1	0.25	>0.05

BMI: body mass index; C-ACT: childhood asthma control test; EFV₁: forced expiratory volume in 1 second; PEF variability: peak expiratory flow variability; sputum SP: sputum levels of substance P.
*Significant.